Lanadelumab
Lanadelumab: A Promising Therapy for Hereditary Angioedema[edit | edit source]
Lanadelumab (INN), marketed under the trade name Takhzyro, is a human monoclonal antibody (class IgG1 kappa) that has garnered significant attention for its potential in the treatment of hereditary angioedema. By targeting plasma kallikrein (pKal), Lanadelumab works towards the prevention of angioedema attacks in affected patients.
Mechanism of Action[edit | edit source]
Lanadelumab exerts its therapeutic action by targeting the plasma kallikrein (pKal). By inhibiting this protein, the drug reduces cleavage of kininogen in the plasma, a critical step implicated in the pathogenesis of hereditary angioedema[1]. This mechanism underpins its role in preventing episodes of angioedema in patients.
Clinical Studies[edit | edit source]
- Phase 1 Trials: In initial clinical evaluations, Lanadelumab exhibited a favorable safety profile. Notably, the drug was associated with a marked reduction in the cleavage of kininogen in the plasma of hereditary angioedema patients[2].
- Ongoing Phase 3 Trials (as of 2017): Building on the positive findings from early-phase trials, two pivotal phase 3 studies are underway. These trials are specifically designed to assess the efficacy of Lanadelumab in preventing acute angioedema attacks in patients with hereditary angioedema[3].
Development and Designation[edit | edit source]
Lanadelumab was originally developed by Dyax Corp, a biopharmaceutical company with a notable track record in antibody research. Subsequent developmental phases have been taken over by Shire, further emphasizing the potential of this molecule.
Signifying its importance and promise, the U.S. FDA has conferred the "breakthrough therapy" designation upon Lanadelumab. Such a designation is reserved for drugs that demonstrate substantial improvements over existing therapies for severe or life-threatening conditions[4].
Conclusion[edit | edit source]
Lanadelumab offers a beacon of hope for patients afflicted with hereditary angioedema, a condition that can be debilitating and, in some instances, life-threatening. With its targeted mechanism of action and encouraging clinical results, the future looks promising for this novel therapeutic antibody.
References[edit | edit source]
- ↑ Zuraw, B.L. (2008). Hereditary angioedema with normal C1 inhibitor: Four types and counting. The Journal of Allergy and Clinical Immunology, 141(4), 884–885.
- ↑ Banerji, A., et al. (2017). Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine, 376(8), 717–728.
- ↑ Riedl, M.A., et al. (2018). Multicenter, randomized, double-blind, placebo-controlled study of lanadelumab for prevention of attacks in hereditary angioedema. JAMA Dermatology, 154(12), 1441–1449.
- ↑ U.S. Food and Drug Administration. (2019). Breakthrough Therapy. Retrieved from https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
